

1 **Comparing dietary and non-dietary source contribution of BPA and DEHP to**
2 **prenatal exposure: A Catalonia (Spain) case study.**

3

4 M. A. Martínez^a, J. Rovira^{a,b}, R. Prasad Sharma^a, M. Nadal^b, M. Schuhmacher^{a,b}, V.
5 Kumar^{a,c}

6

7 ^aEnvironmental Engineering Laboratory, Departament d'Enginyeria Química,
8 Universitat Rovira i Virgili, Av. Països Catalans 26, 43007 Tarragona, Catalonia, Spain.

9 ^bLaboratory of Toxicology and Environmental Health, School of Medicine, IISPV,
10 Universitat Rovira i Virgili, Sant Llorenç 21, 43201 Reus, Catalonia, Spain.

11 ^cIISPV, Hospital Universitari Sant Joan de Reus, Universitat Rovira I Virgili, Reus,
12 Spain.

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30 *Corresponding author at: Environmental Engineering Laboratory, Departament d'Enginyeria
31 Química, Universitat Rovira i Virgili, Tarragona, Catalonia, Spain. Tel.: +34977558576.

32 *E-mail address:* vikas.kumar@urv.cat

33

34 Abstract

35 Bisphenol A (BPA) and Di-(2-ethylhexyl) phthalate (DEHP) are two wide spread
36 chemicals classified as endocrine disruptors (ED). The present study aims to estimate
37 the non-dietary (dermal, non-dietary ingestion and inhalation) exposure to BPA and
38 DEHP for a pregnant women cohort. In addition, to assess the prenatal exposure for
39 the fetus, a physiologically based pharmacokinetic (PBPK) model was used. It was
40 adapted for pregnancy in order to assess the internal dosimetry levels of EDs (BPA
41 and DEHP) in the fetus. Estimates of exposure to BPA and DEHP from all pathways
42 along with their relative importance were provided in order to establish which proportion
43 of the total exposure came from diet and which came from non-dietary exposures. In
44 this study, the different oral dosing scenarios (dietary and non-dietary) were considered
45 keeping inhalation as a continuous exposure case. Total non-dietary mean values were
46 $0.002 \mu\text{g}/\text{kg}_{\text{bw}}/\text{day}$ (0.000; $0.004 \mu\text{g}/\text{kg}_{\text{bw}}/\text{day}$ for 5th and 95th percentile, respectively) for
47 BPA and $0.597 \mu\text{g}/\text{kg}_{\text{bw}}/\text{day}$ ($0.116 \mu\text{g}/\text{kg}_{\text{bw}}/\text{day}$ and $1.506 \mu\text{g}/\text{kg}_{\text{bw}}/\text{day}$ for 5th and 95th
48 percentile, respectively) for DEHP. Indoor environments and especially dust ingestion
49 were the main non-dietary contributors to the total exposure of BPA and DEHP with
50 60% and 81%. However, as expected, diet showed the higher contribution to total
51 exposure with >99.9% for BPA and 63% for DEHP. Although diet was considered the
52 primary source of exposure to BPA and phthalates, it must be taken into account that
53 with non-dietary sources the first-pass metabolism is lacking, so these may be of equal
54 or even higher toxicological relevance than dietary sources.

55 The present study is in the framework of “Health and environmental-wide associations
56 based on large population surveys” (HEALS) project (FP7-603946).

57 Keywords: Bisphenol-A; Di-(2-ethylhexyl) phthalate (DEHP); PBPK modeling; exposure
58 assessment.

59

60

61

62

63

64

65

66

67

68 1. Introduction

69 Bisphenol A (BPA) and Di-(2-ethylhexyl) phthalate (DEHP) are two high volume
70 industrial chemicals used in a wide variety of consumer products. These compounds
71 are defined as non-persistent Endocrine Disrupters (EDs) and are categorized as
72 chemicals of concern by the World Health Organization (WHO, 2010). The exposure to
73 EDs plays a key role in the epigenome shaping of many aspects of the endocrine
74 function (Casati, 2013; Chen et al., 2018). The evidences present in the literature
75 indicate that EDs can affect the different levels of epigenetic control (Sharma et al.,
76 2017) and in some cases can act transgenerationally, if the exposure to EDs occurs
77 during “critical windows of exposure”, especially, the prenatal and the early life period
78 (Sharma et al., 2016; Volle et al., 2015; Watkins et al., 2017). Furthermore, some
79 studies have shown that exposure to these chemicals in the early period of life may
80 cause functional impairment of development and reproduction (Dodson et al., 2012;
81 Meeker, 2012; Sakhi et al., 2014), increase the risk of allergy/asthma (Robinson and
82 Miller, 2015; Sakhi et al., 2014) and also can develop obesity and type 2 diabetes
83 (Casas et al., 2011; De Cock et al., 2014; Myridakis et al., 2016). It is known that fetal
84 exposure is directly related to the mother’s exposure, due to a bi-directional transfer of
85 chemicals between the placenta and fetal plasma (Sharma et al. 2018). Normally
86 placental barrier is considered protective layer against harmful compounds, however, a
87 recent study has found poor barrier mechanism of placenta against some common EDs
88 (Go et al., 2007; Li et al., 2013; Ribeiro et al., 2017).

89 Phthalates such as DEHP are industrial chemicals, which are used in polyvinyl chloride
90 (PVC) plastics, found in products such as shoes, gloves and packing materials as well
91 as in building materials, floorings and wall coverings (Giovanoulis et al.,2018). In
92 addition, they are used in pharmaceuticals products, personal care products (PCPs),
93 paints and adhesives (Bao et al., 2015). All of these applications are related to dermal
94 contact, non-dietary ingestion or inhalation exposure sources. Some studies confirm
95 that DEHP is an important contaminant in dust household; people can be exposed to it
96 via dust ingestion, the exposure through this will be higher for workers in PVC
97 industries (Fromme et al., 2004). It is known that babies and young children are the
98 most vulnerable groups with respect to phthalates due to their developmental status
99 (Giovanoulis G et al., 2018; Sathyanarayana et al., 2008; Zhu et al., 2018).

100 BPA is currently used in polycarbonate plastics, found in materials intended to come
101 into contact with food, like reusable plastic bottles, feeding-bottles, plates, cups,
102 microwave and ovenware (Geens et al., 2009). In addition, we can find BPA in storage
103 containers and epoxy resin linings for food and beverage containers. Furthermore, they
104 are used in thermal papers and paper currencies, medical devices, dental sealants,
105 and PCPs which are related with dermal exposure sources (Geens et al., 2012; Lv et
106 al., 2017). Some studies showed that BPA exposure via dermal route can highly
107 contribute to overall internal exposure (Biedermann et al., 2010; Mielke et al., 2011).
108 Other studies affirm that people who work in offices will be more exposed via dust
109 ingestion or inhalation than others because the levels of BPA in dust offices were
110 almost 5–10 times higher than dust from particular homes (Geens et al., 2009).

111 The human exposure routes to EDs are multiple (Giulivo et al., 2016). Although the
112 major human route of exposure to BPA and DEHP has been shown by several
113 assessments, including the European Food Safety Authority (EFSA), to be the dietary
114 pathway (EFSA, 2013; Geens et al., 2012; Guo et al., 2013). However, some studies
115 confirm that non-dietary sources need to be more thoroughly characterized (EFSA,
116 2015; Geens et al., 2012). Estimates of exposure to DEHP and BPA from all pathways

117 along with their relative importance should be provided in order to establish which
118 proportion of the total exposure comes from diet and which comes from non-dietary
119 exposures. Human exposure to EDs from non-dietary sources, their toxicity, as well as
120 their combined effects, are poorly understood (Larsson et al., 2014).

121 In this study, occupational risk, lifestyle and the use of different PCPs were considered
122 in order to assess the exposure to different pathways (dermal contact, non-dietary
123 ingestion, and inhalation). Sharma et al., (2018) developed a P-PBPK model for BPA
124 including specific pregnancy physiology and both oral and dermal route of exposure.
125 The simulation results were presented to compare the reported data from different
126 cohorts presuming the collection of samples can be from at different time points, in
127 order to explain the inconsistency in biomonitoring data. Moreover, some authors
128 compared the results obtained between real measurements concentrations levels of
129 EDs in the blood reported and the exposure estimates based on PBPK models (Mielke
130 and Gundert-Remy, 2009); the intake estimated were several orders of magnitude
131 lower than the real values in blood reported in the literature. One way to explain this
132 abnormality could be that in the PBPK model they only considered the dietary source,
133 so this could have led to an underestimation of the exposure to these chemicals
134 through non-dietary routes like dermal, inhalation or dust ingestion. However, there are
135 other contributing factors for this difference such as genetic variability, biomonitoring
136 sampling strategy and contamination of sample during analysis.

137 The present study aims to estimate the non-dietary (dermal, non-dietary ingestion and
138 inhalation) exposure to BPA and DEHP for a pregnant women cohort. In addition, to
139 assess the prenatal exposure for the fetus, through all routes (diet and non-dietary) a
140 physiologically based pharmacokinetic (PBPK) model was used. The pregnancy PBPK
141 model structure was adapted from Sharma et al., (2018). Previous work has been
142 extended to estimate the aggregate exposure of these EDs to humans to understand
143 the relative importance of non-dietary exposure. Parameters and structure of the
144 models were kept same as our previous publications (Sharma et al., 2018; Martínez et
145 al., 2017), except nondietary routes (inhalation and dermal) were included. The present
146 study is in the framework of “Health and environmental-wide associations based on
147 large population surveys” (HEALS) project (FP7-603946) and part of the study has
148 been completed in MODELBI project (MINECO funded with ref no AGL2016-78942-
149 R).

150

151 2. Materials and methods

152 2.1. Study population

153 The study population comprises a cohort of pregnant women and ongoing birth cohort.
154 The pregnant women were recruited during the first trimester of pregnancy as part of
155 the European “HEALS” project. The recruitment of pregnant mothers has started in
156 March 2016 and in the present study 72 mother-child pairs from Reus (Tarragona,
157 Spain) were included. Women were informed of the study during their first visit (12th
158 gestational week) to the University Hospital “Sant Joan de Reus”, in Reus (Catalonia,
159 NE Spain). Women were eligible to participate according to the following inclusion
160 criteria: ≥ 16 years old, intention to deliver at the reference hospital, and no problems
161 with the communication language. This study was approved by the Ethical Committee
162 of Clinical Research of the Hospital and a written informed consent was obtained from
163 the participants.

164

165 2.2. Questionnaires and data acquisition

166 At 20th gestational weeks (GW), a PCPs frequency questionnaire was filled in a face-to-
 167 face interview. Different PCPs were included in the questionnaire: a) makeup (face
 168 cream, eyeshadow and liquid foundation), b) lipstick, c) body lotion, d) shampoo, e)
 169 shower gel, f) hair conditioner, g) toothpaste, h) deodorant and i) spray perfume. In
 170 addition, the questionnaires also included in one hand, general characteristics data of
 171 the study population, such as maternal age at delivery, twin pregnancy, maternal body
 172 mass index (BMI), maternal education, social economic status, country of origin, and
 173 marital status. On the other hand, a set of questions targeting to know other sources of
 174 these compounds are included, such as maternal smoking, lifestyle, hours spend
 175 outdoors and indoors and occupational risk. A description of the characteristics of the
 176 study population is shown in Table 1.

177

178 2.3. BPA and DEHP non-dietary assessment

179 2.3.1. Dermal contact exposure

180 The assessment of exposure of BPA and DEHP through dermal contact for pregnant
 181 women population was calculated according to equation 1. We considered all PCPs
 182 previously mentioned.

$$183 \text{ Dermal exposure} = \sum(C_c \times PCP_{fr} \times PCP_a \times ABS \times R_f) / BW_{20GW} \quad \text{Eq. 1}$$

184 Where C_c is the concentration of BPA or DEHP in PCPs (in $\mu\text{g/g}$); PCP_{fr} is the
 185 frequency application (in application/day); PCP_a is the amount per application (in
 186 g/application); ABS is the dermal absorption factor (non-dimensional); R_f is the
 187 retention factor for rinse-off products (non-dimensional); and BW_{20GW} is the body weight
 188 at 20 gestational weeks (in kg). Dermal exposure is given in $\mu\text{g/kg}_{bw}/\text{day}$. Data used to
 189 assess the dermal exposure of BPA and DEHP are summarized in Table 2.

190

191 2.3.2. Non-dietary ingestion exposure

192 Non-dietary ingestion pathways include, on the one hand, dust ingestion that was
 193 calculated according to equation 2.a. On the other hand, exposure through PCPs
 194 ingestion was considered. Lipstick and toothpaste ingestion was assessed according to
 195 equation 2.b.

196

$$197 \text{ Non - dietary ingestion exposure } (Dust_{\text{ingestion}}) = (C_c \times I_r) / BW_{20GW} \quad \text{Eq. 2.a.}$$

$$198 \text{ Non - dietary ingestion exposure } (PCP_{\text{ingestion}}) = (C_c \times PCP_{fr} \times PCP_a \times Ing_f) / BW_{20GW} \\ 199 \quad \text{Eq. 2.b.}$$

200 Where C_c is the concentration of BPA or DEHP in homes dust (in $\mu\text{g/kg}$); I_r is the
 201 Ingestion rate (in kg/day) and BW_{20GW} is the body weight at 20 gestational weeks (in
 202 kg). PCP_{fr} is the frequency application (in application/day); PCP_a is the amount per
 203 application (in g/application) and Ing_f is the ingestion factor (non-dimensional). The total
 204 non-dietary exposure is given in $\mu\text{g/kg}_{bw}/\text{day}$. Table 3 provides data used to assess the
 205 non-dietary ingestion exposure of BPA and DEHP.

206

207

2.3.3. Inhalation exposure

208 The exposure assessment of BPA and DEHP through inhalation for pregnant women
 209 was calculated according to equation 3. We considered levels of BPA and DEHP in the
 210 outdoor and indoor air. In this case, three different scenarios were assessed: sleeping
 211 (3.a), indoors (3.b) and outdoors (3.c) scenarios.

$$212 \text{ Inhalation exposure}_{\text{sleeping}} = (C_c^{\text{indoor}} \times I_{hr_{\text{sleep}}} \times t_{\text{sleep}}) / BW_{20GW} \quad \text{Eq. 3.a}$$

$$213 \text{ Inhalation exposure}_{\text{indoor}} = (C_c^{\text{indoor}} \times I_{hr_{\text{sedentary}}} \times t_{\text{indoor}}) / BW_{20GW} \quad \text{Eq.3.b}$$

$$214 \text{ Inhalation exposure}_{\text{outdoor}} = (C_c^{\text{outdoor}} \times I_{hr_{\text{moderate}}} \times t_{\text{outdoor}}) / BW_{20GW} \quad \text{Eq.3.c}$$

215 Where C_c^{indoor} is the concentration of BPA or DEHP in the indoor air (in $\mu\text{g}/\text{m}^3$);
 216 C_c^{outdoor} is the concentration of BPA or DEHP in the outdoor air (in $\mu\text{g}/\text{m}^3$); $I_{hr_{\text{sleep}}}$ is the
 217 inhalation rate during sleep (in m^3/min); $I_{hr_{\text{sedentary}}}$ is the inhalation rate while sedentary
 218 activities (in m^3/min); $I_{hr_{\text{moderate}}}$ is the inhalation rate during moderate activities (in
 219 m^3/min); t_{sleep} is the mean of time sleeping (in min); t_{indoor} is the mean of time spending
 220 indoor (at work and at home) (in min); t_{outdoor} is the time spending in doing activity
 221 outdoor (in min) and BW_{20GW} is the body weight at 20 gestational weeks (in kg). The
 222 total inhalation exposure is given in $\mu\text{g}/\text{kg}_{\text{bw}}/\text{day}$. Table 4 contains the data used to
 223 assess the inhalation exposure of BPA and DEHP.

224

225 The concentration levels of BPA and DEHP in different PCPs, in dust and air, were
 226 taken from the literature with a preference rule of Spanish values > European values >
 227 other available data. To deal with variability and uncertainty of parameters used,
 228 probabilistic estimation of the dermal, non-dietary ingestion and inhalation exposure
 229 was performed in a probabilistic way. Monte-Carlo simulation is a common approach
 230 used to incorporate variability and uncertainty of the parameters used into the
 231 estimation of human health exposure (Mari et al., 2009; May et al., 2002; Rovira et al.,
 232 2016; Schuhmacher et al., 2001). Table 2, 3 and 4 includes the probabilistic distribution
 233 of parameters for the calculation of human health exposure. Monte-Carlo simulation
 234 was carried out by Oracle Crystal Ball® software. Exposures were calculated based on
 235 the propagation variable of variability and uncertainty given by each parameter
 236 probability function until 100,000 iterations.

237

238 2.4 Tissue dosimetry model (PBPK).

239 The basic structure of pregnant PBPK model has been adapted from Sharma et al.,
 240 (2018) in the current study in order to assess dietary and non-dietary exposure. It
 241 comprises plasma, liver, kidneys, fat, brain, skin, placenta, a rest of the body and a
 242 fetus compartment. Fetus compartment was subcategorized again into liver, brain, and
 243 plasma. All the Physiological parameters during pregnancy are considered to be
 244 dynamic parameters that change due to the growth of mother organs (Abduljalil et al.,
 245 2012; Gentry et al., 2003; Loccisano et al., 2013). The source of exposure to fetuses
 246 was via a free fraction of chemicals into mother's placenta, considering that fetuses'
 247 exposure is directly related to mother's exposure. The placental-fetal unit assumes a
 248 bidirectional transfer process describing chemical transfer between mothers' placenta
 249 to fetuses' plasma and fetuses' plasma to the mothers. Detailed descriptions of

250 standard and pregnancy-specific model equations are adapted from Sharma et al.,
251 (2018). Metabolic kinetic parameters for both mothers and fetuses were previously
252 estimated from in-vitro studies (Martínez et al., 2017; Sharma et al., 2018).

253 Two different sources of exposure were considered for the current study, dietary
254 exposure and the combination of dietary with non-dietary exposure. The dosing
255 considered being inputs for the PBPK model was estimated using Monte Carlo
256 technique for the exposure assessment. It has been considered the six following
257 exposure scenarios of BPA and DEHP: 5th percentile diet; 5th percentile diet + non-diet;
258 Mean diet; Mean diet+ non-diet; 95th percentile diet, and 95th percentile diet + non-diet.
259 For the current study, the routes of exposure were the following: ingestion and dermal
260 exposure that were divided into three equal doses (with 8 hours of the interval). On the
261 other hand, continuous exposure for inhalation was presumed, considering three
262 different inhalation rates (sleeping time, doing sedentary activities and doing moderate
263 activities).

264

265 3. Results and discussion

266

267 3.1 Non-dietary (dermal, non-dietary ingestion and inhalation) exposure to BPA and 268 DEHP.

269 The contribution of dermal contact, non-dietary ingestion, and inhalation to the total
270 non-dietary intake from Reus pregnant mothers' cohort was assessed in a probabilistic
271 way using Monte-Carlo simulation. Figure 1, summarizes the contribution of each non-
272 dietary source to the total exposure of BPA and DEHP.

273 Regarding BPA (Figure 1), the total non-dietary mean value was 0.002 $\mu\text{g}/\text{kg}_{\text{bw}}/\text{day}$
274 (0.000 and 0.004 $\mu\text{g}/\text{kg}_{\text{bw}}/\text{day}$ for 5th and 95th percentile, respectively). Relative mean
275 contributions were 60%, 36% and 4% for non-dietary ingestion, inhalation, and dermal
276 routes, respectively. For DEHP (Figure 1), the total non-dietary mean exposure was
277 0.597 $\mu\text{g}/\text{kg}_{\text{bw}}/\text{day}$ (0.116 $\mu\text{g}/\text{kg}_{\text{bw}}/\text{day}$ and 1.506 $\mu\text{g}/\text{kg}_{\text{bw}}/\text{day}$ for 5th and 95th
278 percentile, respectively). The maximum mean contribution was, again, non-dietary
279 ingestion with 81%, followed by dermal route and inhalation with 15% and 4%,
280 respectively.

281 For both chemicals, BPA and DEHP, non-dietary ingestion was the highest mean
282 relative contributor with 60% and 81%, respectively, of the total non-dietary exposure.
283 These represented a mean non-dietary ingestion exposure of $9.62 \cdot 10^{-4}$ and 0.485
284 $\mu\text{g}/\text{kg}_{\text{bw}}/\text{day}$ for BPA and DEHP, respectively. Non-dietary ingestion route considered
285 the levels of both compounds in homes dust and in PCPs that could be accidentally
286 ingested during their use (lipstick and toothpaste). In both cases, the major contribution
287 (>99.9%) to the total non-dietary ingestion exposure to BPA and DEHP came from
288 home dust ingestion. The average concentration of BPA and DEHP in dust were very
289 high, $2 \cdot 10^3$ and $1.20 \cdot 10^6$ $\mu\text{g}/\text{kg}_{\text{dust}}$, respectively. BPA levels in dust were obtained from
290 Belgian houses (Geens et al., 2009) and phthalate levels in dust came from different
291 European homes (Wormuth et al., 2006). However, similar BPA and DEHP levels in
292 indoor dust were found worldwide (Das et al., 2014; Fromme et al., 2004; Ginsberg and
293 Belleggia, 2017; Kubwabo et al., 2016; Langer et al., 2014; Loganathan and Kannan,
294 2011). The high contribution of dust in the total DEHP non-dietary ingestion exposure is
295 due to phthalates, which are used as plasticizers in numerous consumer products,
296 commodities, and building materials. Consequently, phthalates are found in human

297 residential and occupational environments in high concentrations (Wormuth et al.,
298 2006). As well as DEHP, the high contribution of dust in the total BPA non-dietary
299 ingestion exposure is due to BPA is used in a variety of household applications.
300 Through manufacture and usage, these contaminants can leach into the environment
301 and can be deposited in the indoor dust (Geens et al., 2009). It was assumed that
302 consumers accidentally ingest small amounts of PCPs. So, it was estimated the
303 scenario for non-dietary ingestion using information about the amounts cosmetics
304 ingested daily (Table 3), and the DEHP and BPA concentrations in PCP. No much
305 information was available on how much PCPs are ingested daily and also it was not
306 many literature data about concentration levels of these two EDs in different cosmetic
307 products. Only data regarding DEHP in lipstick and BPA in toothpaste content were
308 found. Therefore, it was only considered the accidental ingestion of these two
309 cosmetics, lipstick and toothpaste, during their use. Results showed that the
310 contribution to this kind of ingestion to the total DEHP and BPA non-dietary ingestion
311 were insignificant (0.07% and 0.01% for BPA and DEHP, respectively) compared to
312 total non-dietary ingestion and also with the dietary total intake. However, more
313 bibliographic data is needed to be able to carry out a good exposure assessment.

314 According to BPA, inhalation was the second greatest contributor to the total exposure
315 with an exposure of $5.90 \cdot 10^{-4}$ $\mu\text{g}/\text{kg}_{\text{bw}}/\text{day}$, that meant the 36% of the total non-dietary
316 exposure. In this case, three different scenarios were assessed: indoor, outdoor and
317 sleeping inhalation exposure that showed a contribution to total BPA inhalation
318 exposure of 37%, 51%, and 12%, respectively. Inhalation exposure was lower than the
319 dust exposure; this can be due to BPA has a comparatively low vapour pressure. As a
320 result, concentrations of BPA in the air can be expected to be low and it will be present
321 mainly in the particulate phase, adsorbed to dust (EFSA, 2013). Finally, dermal contact
322 was the exposure route that contributed the least (4%) to the total mean non-dietary
323 BPA exposure, with a dose of $6.39 \cdot 10^{-5}$ $\mu\text{g}/\text{kg}_{\text{bw}}/\text{day}$. Among all the PCPs, face cream
324 (39%), shower gel (20%) and body lotion (18%) have the higher contribution. In
325 Europe, BPA is not allowed as an ingredient in cosmetics (Regulation (EC) no.
326 1223/2009 of the European Parliament and of the Council of 30 November 2009 on
327 cosmetic products). However, if BPA is present in the packaging (e.g. polycarbonates
328 plastic (PC) packaging), it could migrate into the cosmetic products (EFSA, 2013). It
329 must be taken into account that dermal absorption of BPA can reach 95-100% if BPA is
330 applied dissolved in ethanol, because ethanol may act as a transport mediator for BPA
331 into the skin, thus enhancing the absorption fraction. In addition, this property of
332 dissolving in ethanol can be found in similar compounds in the formulation of creams
333 and body lotions (EFSA, 2013).

334 Regarding DEHP, dermal contact with a mean value of 0.087 $\mu\text{g}/\text{kg}_{\text{bw}}/\text{day}$, was the
335 second greatest contributor to the total non-dietary exposure (15%). In this exposure
336 assessment, perfume and deodorant were the items which contribute more to the total
337 DEHP dermal exposure, with 36% and 33%. The quite high presence of these ED is
338 due to phthalates in general, are added as humectants, emollients, or skin penetration
339 enhancers, which are very common in perfumes and fragrances (Koo and Lee, 2004).
340 Finally, DEHP inhalation (0.025 $\mu\text{g}/\text{kg}_{\text{bw}}/\text{day}$) was the item which contributed less (4%)
341 to the DEHP mean non-dietary exposure. Indoor exposure and sleeping inhalation
342 exposure had a relative contribution of 61% and 36%, respectively. Other authors
343 (Wormuth et al., 2006) found that accidental ingestion of PCPs are the major sources
344 of exposure to DEHP in all consumer groups that we estimated. Although the food is
345 the dominating source of exposure to DEHP in all consumer groups (Wormuth et al.,
346 2006).

347 Indoor environment (home dust ingestion and inhalation (indoor and sleeping)) were
348 the principal source of BPA and DEHP of non-dietary exposure with a relative
349 contribution of 78% and 85%, respectively. PCPs contribute with 4% and 15% to total
350 mean non-dietary exposure of BPA and DEHP, respectively, almost exclusively
351 through dermal contact. Finally, outdoor environment (through outdoor inhalation)
352 showed a contribution of 18% and <0.1% to total mean non-dietary exposure for BPA
353 and DEHP, respectively.

354 3.2 Dietary exposure vs non-dietary exposure

355 Figure 2, shows the comparison between total dietary exposure and non-dietary
356 (dermal, non-dietary ingestion and inhalation) exposure to BPA and DEHP. Data from
357 the dietary exposure was previously estimated using the same cohort population
358 (Martínez et al., 2017).

359 Regarding BPA, mean dietary daily intake from Reus (Tarragona, Spain) cohort was
360 0.715 $\mu\text{g}/\text{kg}_{\text{bw}}/\text{day}$ (Martínez et al., 2017), and the mean exposure estimated for non-
361 dietary ingestion, inhalation, and dermal contact were $9.62 \cdot 10^{-4}$, $5.90 \cdot 10^{-4}$, $6.39 \cdot 10^{-5}$
362 $\mu\text{g}/\text{kg}_{\text{bw}}/\text{day}$, respectively. In general, in the present study according to non-dietary
363 exposure, the maximum exposure estimated for BPA was 0.0072 $\mu\text{g}/\text{kg}_{\text{bw}}/\text{day}$ and the
364 95% of the population were under 0.0040 $\mu\text{g}/\text{kg}_{\text{bw}}/\text{day}$. Non-dietary exposure practically
365 did not contribute to the total exposure (0.2%). In other words, diet was the greatest
366 contributor to the total exposure (99.8%) (Figure 2). However, it is important to know
367 that in this study thermal paper was not considered in dermal exposure estimation,
368 which is considered as a potential exposure source for BPA in the EU by the EFSA,
369 2015.

370 BPA is conjugated in the liver by glucuronidation and sulfation, “total BPA” stands for
371 the sum of conjugated and unconjugated forms. For further risk assessment, these two
372 forms need to be distinguished, the unconjugated BPA is more toxicologically relevant.
373 The contribution of dermal and inhalation sources to internal exposure to total BPA is
374 considerably smaller compared to oral sources. However, with dermal and inhalation
375 exposure the first-pass metabolism is lacking, regardless of the small contribution of
376 non-dietary sources to total BPA, their contribution to the plasma concentration levels
377 of unconjugated BPA may be considerable. Kinetic studies have shown that in
378 monkeys only around 1% of orally absorbed BPA becomes systemically bioavailable as
379 unconjugated BPA (Fisher et al., 2011), whereas after dermal absorption, practically all
380 absorbed BPA (around 10% of the external dermal dose, Demierre et al., 2012) initially
381 becomes bioavailable as unconjugated BPA. For that reason, non-dietary sources may
382 be of equal or even higher toxicological relevance than dietary sources (Lu et al., 2017;
383 Völkel et al., 2002; von Goetz et al., 2017). Considering diet and non-diet sources the
384 mean of the total exposure was 0.72 $\mu\text{g}/\text{kg}_{\text{bw}}/\text{day}$ and the 5th and 95th percentile of the
385 total exposure were 0.28 and 1.41 $\mu\text{g}/\text{kg}_{\text{bw}}/\text{day}$ (Figure 2).

386 Regarding DEHP, Figure 2 shows that non-dietary sources contribute with 37 % of the
387 total exposure. The mean dietary daily intake of DEHP exposure from Reus cohort was
388 1.00 $\mu\text{g}/\text{kg}_{\text{bw}}/\text{day}$ (Martínez et al., 2017), and the mean exposure estimated for non-
389 dietary ingestion, inhalation, and dermal contact were 0.485, 0.025, 0.087 $\mu\text{g}/\text{kg}_{\text{bw}}/\text{day}$
390 respectively. According to total non-dietary exposure, the maximum dose was 3.86
391 $\mu\text{g}/\text{kg}_{\text{bw}}/\text{day}$ and the 95th percentile was 1.51 $\mu\text{g}/\text{kg}_{\text{bw}}/\text{day}$, and mean value was 0.60
392 $\mu\text{g}/\text{kg}_{\text{bw}}/\text{day}$. Considering diet and non-diet sources the mean of the total exposure was
393 1.60 $\mu\text{g}/\text{kg}_{\text{bw}}/\text{day}$ and the 5th and 95th of the total exposure were 0.52 and 3.52
394 $\mu\text{g}/\text{kg}_{\text{bw}}/\text{day}$, respectively (Figure 2).

395

396 EFSA published its comprehensive re-evaluation of BPA exposure and toxicity, in
397 January 2015, and established a tolerable daily intake (TDI) of 4 $\mu\text{g}/\text{kg}_{\text{bw}}/\text{day}$ for BPA
398 (EFSA, 2015). On the other hand, EFSA and the European Chemicals Agency (ECHA)
399 established the TDI for DEHP to 50 $\mu\text{g}/\text{kg}_{\text{bw}}/\text{day}$ (ECHA, 2010; EFSA, 2015). Only the
400 non-dietary ingestion estimated data from this study can be compared with this EFSA
401 and ECHA tolerable values because the TDI values are concerned about “daily intake”.
402 Therefore, in this study, the maximum value estimated for BPA non-dietary ingestion
403 exposure was 0.0052 $\mu\text{g}/\text{kg}_{\text{bw}}/\text{day}$ and the 95% of the population were below 0.0028
404 $\mu\text{g}/\text{kg}_{\text{bw}}/\text{day}$. Whereas, for DEHP, the maximum value estimated for non-dietary
405 ingestion exposure was 3.39 $\mu\text{g}/\text{kg}_{\text{bw}}/\text{day}$ and the 95% of the population were under
406 1.24 $\mu\text{g}/\text{kg}_{\text{bw}}/\text{day}$. These values for BPA and DEHP estimated in our study were far
407 away from the tolerable values of the EFSA and ECHA. Although BPA and DEHP non-
408 dietary ingestion exposure assessment values were under the tolerable established, it
409 is important to take into account that non-dietary ingestion and, in general, non-dietary
410 levels must be added to the total dietary exposure assessment, in order to make a
411 good exposure estimation.

412

413 3.3 Internal dosimetry

414 The chemicals' dose inputs considered to run the P-PBPK, were probabilistically
415 estimated by Monte-Carlo simulation (Section 2.4). From probabilistic distribution, six
416 total scenarios were selected for BPA and DEHP: the 5th percentile diet; the 5th
417 percentile diet + non-diet; mean diet; mean diet + non-diet; the 95th percentile diet and
418 the 95th percentile diet + non-diet. The outputs from the model simulation were selected
419 considering the metabolites generated, their toxicity, gestational period and ability to
420 reach the fetus. For this reason, only free BPA and MEHP (a metabolite of DEHP) were
421 considered. The simulation data were taken from pregnant women and fetus for 24 h
422 during the 24th gestational week. This period was selected because at this time fetus
423 organs are more developed and able to incorporate right biological process. This helps
424 us to explain the difference in metabolic processes in mothers and fetuses. Normally,
425 at the early stage of pregnancy, for both BPA and MEHP, fetus plasma concentration
426 level is higher due to low or no metabolic activities in the fetus (Gauderat et al., 2016;
427 Latini et al., 2003). In order to be near to a real scenario, a dietary, and non-dietary
428 (dermal and ingestion) exposure were divided into three equal doses, along with
429 continuous exposure of non-dietary source (inhalation) and were simulated (Figure 3)
430 in the case of BPA. On the other hand, DEHP metabolite MEHP time plasma
431 concentration profile in case of both mother and fetus is showed in Figure 4, the result
432 of single-dose intake of dietary and non-dietary. In this case, inhalation was considered
433 again as continuous exposure, the simulated concentration curves show a sharp peak
434 concentration o within 1 h of intake. It is known that metabolic activity in the fetus is
435 lower compared to mother's metabolism (Heindel et al., 2017). For that reason,
436 concentration levels of both chemicals in the fetus' plasma were higher than in the
437 mother. Therefore, BPA and MEHP stay longer in the fetal body, which may cause
438 higher risk to fetuses and makes the fetus more vulnerable to the exposure. A similar
439 trend has been observed by Sharma et al., (2018).

440 4. Conclusions

441 Regarding BPA non-dietary exposure was 0.002 $\mu\text{g}/\text{kg}_{\text{bw}}/\text{day}$, with the greatest
442 contribution coming from non-dietary ingestion with 60%, followed by inhalation with

443 36%. Finally, dermal exposure was the one that contributed the least with 4%.
444 However, in this study, the thermal paper was not considered in dermal exposure
445 estimation, which is considered as a potential exposure source for the general
446 population (EFSA, 2015). According to DEHP non-dietary exposure (0.597
447 $\mu\text{g}/\text{kg}_{\text{bw}}/\text{day}$), the maximum contributor was non-dietary ingestion with 81%, followed by
448 dermal contact with 15% and inhalation with 4%. As expected, diet was the main
449 contributor to total exposure to both chemicals. Regarding DEHP, non-dietary sources
450 contribute 37% of the total exposure. The non-dietary exposure to BPA practically did
451 no contribute to the total exposure (0.22%). Indoor environment, dust ingestion, and
452 indoor air inhalation was the main contributor to non-dietary exposure to both ED (78%
453 for BPA and 85% for DEHP) meanwhile PCPs contribute in 4% and 15%, for BPA and
454 DEHP, respectively. However, with dermal absorption that passes the first-pass
455 metabolism, dermal sources may be of equal or even higher toxicological relevance
456 than dietary sources (Völkel et al., 2002; von Goetz et al., 2017). Only the non-dietary
457 ingestion estimated data in combination with other dietary exposure from this study can
458 be comparable with EFSA and ECHA tolerable values because the TDI values are
459 concerned about "daily intake". Although BPA and DEHP non-dietary ingestion
460 exposure assessment values were under the tolerable established, it is important to
461 take into account that non-dietary exposure levels must be added to the total dietary
462 exposure assessment, in order to make a good exposure estimation.

463 According to internal dosimetry, six different scenarios were considered in order to run
464 the PBPK model. When the simulation considered diet + non-diet scenarios, the
465 concentration levels of BPA and MEHP (main metabolite of DEHP) increased
466 considerably in plasma. In addition, in fetus' plasma, the concentration of both
467 chemicals reached levels much higher than those seen previously in mothers. The low
468 metabolic activity in fetus led to maintain a continuous concentration in time. Therefore,
469 this can make the fetus more vulnerable to the exposure compared with their mothers.

470 The ongoing research is to validate the PBPK model with biological samples from this
471 cohort and demonstrate that this methodology allows the determination of BPA and
472 MEHP for monitoring in biological matrices, such as plasma and urine. Finally,
473 demonstrate that PBPK model can predict the prenatal exposure of the child/fetus to
474 EDs. To conclude, on the one hand, strategies must be presented in order to reduce
475 their exposure. Restrictions must be imposed to regulate the production and use of
476 products related especially with childcare and pregnant women.

477

478 Acknowledgements

479 Authors thank all pregnant women who participate in this study. The research
480 leading to these results has partially funded from the European Community's Seventh
481 Framework Programme (FP7/2007-2013) under Grant Agreement No. 603946-2
482 (HEALS project) and the Spanish Ministry of Economy and Competitiveness for the
483 MODELBI project (Ref. No. AGL2016-78942-R). V. Kumar and J. Rovira received
484 funds from Health Department of Catalonia Government through "Pla Estratègic de
485 Recerca i Innovació en salut" (PERIS 2016-2020).

486

487 References

488 Abduljalil, K., Furness, P., Johnson, T.N., Rostami-Hodjegan, A., Soltani, H., 2012.

- 489 Anatomical, Physiological and Metabolic Changes with Gestational Age during
490 Normal Pregnancy. *Clin. Pharmacokinet.* 51, 365–396. doi:10.2165/11597440-
491 000000000-00000
- 492 Bao, J., Wang, M., Ning, X., Zhou, Y., He, Y., Yang, J., Gao, X., Li, S., Ding, Z., Chen,
493 B., 2015. Phthalate concentrations in personal care products and the cumulative
494 exposure to female adults and infants in Shanghai. *J. Toxicol. Environ. Health. A*
495 78, 325–41. doi:10.1080/15287394.2014.968696
- 496 Biedermann, S., Tschudin, P., Grob, K., 2010. Transfer of bisphenol A from thermal
497 printer paper to the skin. *Anal. Bioanal. Chem.* 398, 571–576.
498 doi:10.1007/s00216-010-3936-9
- 499 Cacho, J.I., Campillo, N., Viñas, P., Hernández-Córdoba, M., 2013. Stir bar sorptive
500 extraction with EG-Silicone coating for bisphenols determination in personal care
501 products by GC-MS. *J. Pharm. Biomed. Anal.* doi:10.1016/j.jpba.2013.02.023
- 502 Casas, L., Fernández, M.F., Llop, S., Guxens, M., Ballester, F., Olea, N., Irurzun, M.B.,
503 Rodríguez, L.S.M., Riaño, I., Tardón, A., Vrijheid, M., Calafat, A.M., Sunyer, J.,
504 2011. Urinary concentrations of phthalates and phenols in a population of Spanish
505 pregnant women and children. *Environ. Int.* 37, 858–866.
506 doi:10.1016/j.envint.2011.02.012
- 507 Casati, L., 2013. Epigenetics and PCBs. *Endocr. Disruptors* 1, e27347-1-e27347-4.
508 doi:10.4161/endo.27347
- 509 Chen, C.-H., Jiang, S.S., Chang, I.-S., Wen, H.-J., Sun, C.-W., Wang, S.-L., 2018.
510 Association between fetal exposure to phthalate endocrine disruptor and genome-
511 wide {DNA} methylation at birth. *Environ. Res.* 162, 261–270.
512 doi:https://doi.org/10.1016/j.envres.2018.01.009
- 513 Das, M.T., Ghosh, P., Thakur, I.S., 2014. Intake estimates of phthalate esters for South
514 Delhi population based on exposure media assessment. *Environ. Pollut.* 189,
515 118–125. doi:10.1016/j.envpol.2014.02.021
- 516 De Cock, M., de Boer, M.R., Lamoree, M., Legler, J., van de Bor, M., 2014. First year
517 growth in relation to prenatal exposure to endocrine disruptors - A dutch
518 prospective cohort study. *Int. J. Environ. Res. Public Health* 11, 7001–7021.
519 doi:10.3390/ijerph110707001
- 520 Demierre, A.L., Peter, R., Oberli, A., Bourqui-Pittet, M., 2012. Dermal penetration of
521 bisphenol A in human skin contributes marginally to total exposure. *Toxicol. Lett.*
522 213, 305–308. doi:10.1016/j.toxlet.2012.07.001
- 523 Dodson, R.E., Nishioka, M., Standley, L.J., Perovich, L.J., Brody, J.G., 2012. Review
524 Endocrine Disruptors and Asthma-Associated Chemicals in Consumer Products
525 120, 935–944.
- 526 ECHA, 2010. Review of new available information for Bis (2-Ethylhexyl) Phthalate
527 (DEHP). Evaluation of new scientific evidence concerning the restrictions
528 contained in Annex XVII to Regulation (Ec) No 1907/2006 (Reach). ECHA 2006,
529 1–24.
- 530 EFSA, 2015. Scientific Opinion on the risks to public health related to the presence of
531 bisphenol A (BPA) in foodstuffs: Executive summary. *EFSA J.* 13, 1–621.
532 doi:doi:10.2903/j.efsa.2015.3978
- 533 EFSA, 2013. Draft Scientific Opinion on the risks to public health related to the
534 presence of bisphenol A (BPA) in foodstuffs– Part: exposure assessment. *EFSA*
535 *J.* 314. doi:No EFSA-Q-2012-00423

- 536 Esteve, C., Herrero, L., Gómara, B., Quintanilla-López, J.E., 2016. Fast and
537 simultaneous determination of endocrine disrupting compounds by ultra-high
538 performance liquid chromatography-tandem mass spectrometry. *Talanta* 146,
539 326–334. doi:10.1016/j.talanta.2015.08.064
- 540 Fisher, J.W., Twaddle, N.C., Vanlandingham, M., Doerge, D.R., 2011. Pharmacokinetic
541 modeling : Prediction and evaluation of route dependent dosimetry of bisphenol A
542 in monkeys with extrapolation to humans. *Toxicol. Appl. Pharmacol.* 257, 122–
543 136. doi:10.1016/j.taap.2011.08.026
- 544 Franzen, A., Van Landingham, C., Greene, T., Plotzke, K., Gentry, R., 2016. A global
545 human health risk assessment for Decamethylcyclopentasiloxane (D5). *Regul.*
546 *Toxicol. Pharmacol.* 74, S25–S43. doi:10.1016/j.yrtph.2015.10.023
- 547 Fromme, H., Lahrz, T., Piloty, M., Gebhart, H., Oddoy, A., Ruden, H., 2004.
548 Occurrence of phthalates and musk fragrances in indoor air and dust from
549 apartments and kindergartens in Berlin (Germany). *Indoor Air* 14, 188–195.
550 doi:10.1111/j.1600-0668.2004.00223.x
- 551 Gauderat, G., Picard-Hagen, N., Toutain, P.L., Corbel, T., Viguié, C., Puel, S., Lacroix,
552 M.Z., Mindeguia, P., Bousquet-Melou, A., Gayraud, V., 2016. Bisphenol A
553 glucuronide deconjugation is a determining factor of fetal exposure to bisphenol A.
554 *Environ. Int.* 86, 52–59. doi:10.1016/j.envint.2015.10.006
- 555 Geens, T., Aerts, D., Berthot, C., Bourguignon, J.P., Goeyens, L., Lecomte, P.,
556 Maghuin-Rogister, G., Pironnet, A.M., Pussemier, L., Scippo, M.L., Van Looc, J.,
557 Covaci, A., 2012. A review of dietary and non-dietary exposure to bisphenol-A.
558 *Food Chem. Toxicol.* doi:10.1016/j.fct.2012.07.059
- 559 Geens, T., Roosens, L., Neels, H., Covaci, A., 2009. Assessment of human exposure
560 to Bisphenol-A, Triclosan and Tetrabromobisphenol-A through indoor dust intake
561 in Belgium. *Chemosphere* 76, 755–760. doi:10.1016/j.chemosphere.2009.05.024
- 562 Gentry, P.R., Covington, T.R., Clewell, H.J., 2003. Evaluation of the potential impact of
563 pharmacokinetic differences on tissue dosimetry in offspring during pregnancy and
564 lactation. *Regul. Toxicol. Pharmacol.* 38, 1–16. doi:10.1016/S0273-
565 2300(03)00047-3
- 566 Ginsberg, G.L., Belleggia, G., 2017. Use of Monte Carlo analysis in a risk-based
567 prioritization of toxic constituents in house dust. *Environ. Int.* 1–13.
568 doi:10.1016/j.envint.2017.06.009
- 569 Giovanoulis G., Bui T., Xu F., Papadopoulou E., Padilla-Sanchez J.A., Covaci A., Haug
570 L.S., Cousins A.P., Magnér J., Cousins I.T., de W.C.A., 2018. Multi-pathway
571 human exposure assessment of phthalate esters and DINCH Georgios
572 Giovanoulis. *Environ. Int.* 112, 115–126. doi:10.1016/j.envint.2017.12.016
- 573 Giulivo, M., Lopez, M., Alda, D., Capri, E., Barceló, D., 2016. Human exposure to
574 endocrine disrupting compounds : Their role in reproductive systems , metabolic
575 syndrome and breast cancer . A review. *Environ. Res.* 151, 251–264.
576 doi:10.1016/j.envres.2016.07.011
- 577 Go, B., Herrero, L., Ramos, J.J., Mateo, J.R., Ferna, M.A., Gonza, M.J., 2007.
578 Distribution of Polybrominated Diphenyl Ethers in Human Umbilical Cord Serum ,
579 Paternal Serum , Maternal Serum , Placentas , and Breast Milk from Madrid
580 Population , Spain 41, 6961–6968.
- 581 Guo, Y., Kannan, K., 2013. A survey of phthalates and parabens in personal care
582 products from the United States and its implications for human exposure. *Environ.*

- 583 Sci. Technol. 47, 14442–9. doi:10.1021/es4042034
- 584 Guo, Y., Wang, L., Kannan, K., 2013. Phthalates and parabens in personal care
585 products from China: Concentrations and human exposure. Arch. Environ.
586 Contam. Toxicol. 66, 113–119. doi:10.1007/s00244-013-9937-x
- 587 Heindel, J.J., Blumberg, B., Cave, M., Machtinger, R., Mantovani, A., Mendez, M.A.,
588 Nadal, A., Palanza, P., Panzica, G., Sargis, R., Vandenberg, L.N., vom Saal, F.,
589 2017. Metabolism disrupting chemicals and metabolic disorders. Reprod. Toxicol.
590 68, 3–33. doi:10.1016/j.reprotox.2016.10.001
- 591 Institut d'Estadística de Catalunya, 2012. Enquesta de l'ús del temps 2010-2011:
592 principals resultats. Estadística Soc. 155.
- 593 Koo, H.J., Lee, B.M., 2004. Estimated Exposure To Phthalates in Cosmetics and Risk
594 Assessment. J. Toxicol. Environ. Heal. Part A 67, 1901–1914.
595 doi:10.1080/15287390490513300
- 596 Kubwabo, C., Rasmussen, P.E., Fan, X., Kosarac, I., Grenier, G., Coleman, K., 2016.
597 Simultaneous quantification of bisphenol A, alkylphenols and alkylphenol
598 ethoxylates in indoor dust by gas chromatography-tandem mass spectrometry and
599 a comparison between two sampling techniques. Anal. Methods 8, 4093–4100.
600 doi:10.1039/C6AY00774K
- 601 Langer, S., Bekö, G., Weschler, C.J., Brive, L.M., Toftum, J., Callesen, M., Clausen,
602 G., 2014. Phthalate metabolites in urine samples from Danish children and
603 correlations with phthalates in dust samples from their homes and daycare
604 centers. Int. J. Hyg. Environ. Health. doi:10.1016/j.ijheh.2013.03.014
- 605 Larsson, K., Ljung Björklund, K., Palm, B., Wennberg, M., Kaj, L., Lindh, C.H.,
606 Jönsson, B.A.G., Berglund, M., 2014. Exposure determinants of phthalates,
607 parabens, bisphenol A and triclosan in Swedish mothers and their children.
608 Environ. Int. 73, 323–333. doi:10.1016/j.envint.2014.08.014
- 609 Latini, G., De Felice, C., Presta, G., Del Vecchio, A., Paris, I., Ruggieri, F., Mazzeo, P.,
610 2003. Exposure to Di(2-ethylhexyl)phthalate in humans during pregnancy: A
611 preliminary report. Biol. Neonate 83, 22–24. doi:10.1159/000067012
- 612 Li, L., Chen, L., Meng, X., Chen, B., Chen, S., Zhao, Y., Zhao, L., 2013. Exposure
613 Levels of Environmental Endocrine Disruptors in Mother-Newborn Pairs in China
614 and Their Placental Transfer Characteristics 8, 1–9.
615 doi:10.1371/journal.pone.0062526
- 616 Liao, C., Kannan, K., 2014. A survey of alkylphenols, bisphenols, and triclosan in
617 personal care products from China and the United States. Arch. Environ. Contam.
618 Toxicol. 67, 50–59. doi:10.1007/s00244-014-0016-8
- 619 Loccisano, A.E., Longnecker, M.P., Campbell, J.L., Andersen, M.E., Clewell, H.J.,
620 2013. Development of Pbpk Models for PFOA and PFOS for Human Pregnancy
621 and Lactation Life Stages. J. Toxicol. Environ. Heal. Part A 76, 25–57.
622 doi:10.1080/15287394.2012.722523
- 623 Loganathan, S.N., Kannan, K., 2011. Occurrence of bisphenol a in indoor dust from
624 two locations in the Eastern United States and implications for human exposures.
625 Arch. Environ. Contam. Toxicol. 61, 68–73. doi:10.1007/s00244-010-9634-y
- 626 Loretz, L., Api, A.M., Barraj, L., Burdick, J., Davis, D.A., Dressler, W., Gilberti, E.,
627 Jarrett, G., Mann, S., Laurie Pan, Y.H., Re, T., Renskers, K., Scrafford, C., Vater,
628 S., 2008. Exposure data for personal care products: Hairspray, spray perfume,
629 liquid foundation, shampoo, body wash, and solid antiperspirant. Food Chem.

- 630 Toxicol. 44, 2008–2018. doi:10.1016/j.fct.2006.06.029
- 631 Loretz, L.J., Api, A.M., Babcock, L., Barraj, L.M., Burdick, J., Cater, K.C., Jarrett, G.,
632 Mann, S., Pan, Y.H.L., Re, T.A., Renskers, K.J., Scrafford, C.G., 2008. Exposure
633 data for cosmetic products: Facial cleanser, hair conditioner, and eye shadow.
634 Food Chem. Toxicol. 46, 1516–1524. doi:10.1016/j.fct.2007.12.011
- 635 Loretz, L.J., Api, A.M., Barraj, L.M., Burdick, J., Dressler, W.E., Gettings, S.D., Han
636 Hsu, H., Pan, Y.H.L., Re, T.A., Renskers, K.J., Rothenstein, A., Scrafford, C.G.,
637 Sewall, C., 2005. Exposure data for cosmetic products: Lipstick, body lotion, and
638 face cream. Food Chem. Toxicol. 43, 279–291. doi:10.1016/j.fct.2004.09.016
- 639 Lu, S., Yu, Y., Ren, L., Zhang, X., Liu, G., Yu, Y., 2017. Estimation of intake and uptake
640 of bisphenols and triclosan from personal care products by dermal contact. Sci.
641 Total Environ. 1–8. doi:10.1016/j.scitotenv.2017.10.088
- 642 Lv, Y., Lu, S., Dai, Y., Rui, C., Wang, Y., Zhou, Y., Li, Y., Pang, Q., Fan, R., 2017.
643 Higher dermal exposure of cashiers to BPA and its association with DNA oxidative
644 damage. Environ. Int. 98, 69–74. doi:10.1016/j.envint.2016.10.001
- 645 Mari, M., Nadal, M., Schuhmacher, M., Domingo, J.L., 2009. Exposure to heavy metals
646 and PCDD/Fs by the population living in the vicinity of a hazardous waste landfill
647 in Catalonia, Spain: Health risk assessment. Environ. Int. 35, 1034–1039.
648 doi:10.1016/j.envint.2009.05.004
- 649 Martínez, M.A., Rovira, J., Sharma, R.P., Nadal, M., Schuhmacher, M., Kumar, V.,
650 2017. Prenatal exposure estimation of BPA and DEHP using integrated external
651 and internal dosimetry: A case study. Environ. Res. 158, 566–575.
652 doi:10.1016/j.envres.2017.07.016
- 653 May, L.M., Gaborek, B., Pitrat, T., Peters, L., 2002. Derivation of risk based wipe
654 surface screening levels for industrial scenarios. Sci. Total Environ. 288, 65–80.
655 doi:10.1016/S0048-9697(01)01117-2
- 656 McNamara, C., Rohan, D., Golden, D., Gibney, M., Hall, B., Tozer, S., Safford, B.,
657 Coroama, M., Leneveu-Duchemin, M.C., Steiling, W., 2007. Probabilistic
658 modelling of European consumer exposure to cosmetic products. Food Chem.
659 Toxicol. 45, 2086–2096. doi:10.1016/j.fct.2007.06.037
- 660 Meeker, J., 2012. Exposure to environmental endocrine disruptors and child
661 development. Arch. Pediatr. Adolesc. ... 166, E1–E7.
662 doi:10.1001/archpediatrics.2012.241.Exposure
- 663 Mielke, H., Gundert-Remy, U., 2009. Bisphenol A levels in blood depend on age and
664 exposure. Toxicol. Lett. 190, 32–40. doi:10.1016/j.toxlet.2009.06.861
- 665 Mielke, H., Partosch, F., Gundert-Remy, U., 2011. The contribution of dermal exposure
666 to the internal exposure of bisphenol A in man. Toxicol. Lett. 204, 190–198.
667 doi:10.1016/j.toxlet.2011.04.032
- 668 Myridakis, A., Chalkiadaki, G., Fotou, M., Kogevinas, M., Chatzi, L., Stephanou, E.G.,
669 2016. Exposure of Preschool-Age Greek Children (RHEA Cohort) to Bisphenol A,
670 Parabens, Phthalates, and Organophosphates. Environ. Sci. Technol. 50, 932–
671 941. doi:10.1021/acs.est.5b03736
- 672 Ribeiro, E., Ladeira, C., Viegas, S., 2017. EDCs Mixtures: A Stealthy Hazard for
673 Human Health? Toxics 5, 5. doi:10.3390/toxics5010005
- 674 Robinson, L., Miller, R., 2015. The Impact of Bisphenol A and Phthalates on Allergy,
675 Asthma, and Immune Function: a Review of Latest Findings. Curr. Environ. Heal.

- 676 reports 2, 379–87. doi:10.1007/s40572-015-0066-8
- 677 Rovira, J., Roig, N., Nadal, M., Schuhmacher, M., Domingo, J.L., 2016. Human health
678 risks of formaldehyde indoor levels: An issue of concern. *J. Environ. Sci. Heal.*
679 *Part a-Toxic/Hazardous Subst. Environ. Eng.* 51, 357–363.
680 doi:10.1080/10934529.2015.1109411
- 681 Sakhi, A.K., Lillegaard, I.T.L., Voorspoels, S., Carlsen, M.H., Løken, E.B., Brantsæter,
682 A.L., Haugen, M., Meltzer, H.M., Thomsen, C., 2014. Concentrations of phthalates
683 and bisphenol A in Norwegian foods and beverages and estimated dietary
684 exposure in adults. *Environ. Int.* doi:10.1016/j.envint.2014.08.005
- 685 Salapasidou, M., Samara, C., Voutsas, D., 2011. Endocrine disrupting compounds in the
686 atmosphere of the urban area of Thessaloniki, Greece. *Atmos. Environ.* 45, 3720–
687 3729. doi:10.1016/j.atmosenv.2011.04.025
- 688 Sathyanarayana, S., Calafat, A.M., Liu, F., Swan, S.H., 2008. Maternal and infant
689 urinary phthalate metabolite concentrations: Are they related? *Environ. Res.* 108,
690 413–418. doi:10.1016/j.envres.2008.07.002
- 691 SCCS, 2010. The SCCS's notes of guidance for the testing of cosmetic ingredients.
692 *Sci. Comm. Consum. Saf.* SCCS 112.
- 693 Schuhmacher, M., Meneses, M., Xifr, A., Domingo, J.L., 2001. The use of Monte-Carlo
694 simulation techniques for risk assessment: study of a municipal waste incinerator.
695 *Chemosphere* 43, 787–799.
- 696 Sharma, R.P., Schuhmacher, M., Kumar, V., 2018. The development of a pregnancy
697 PBPK Model for Bisphenol A and its evaluation with the available biomonitoring
698 data. *Sci. Total Environ.* 624, 55–68. doi:10.1016/j.scitotenv.2017.12.023
- 699 Sharma, R.P., Schuhmacher, M., Kumar, V., 2017. Developing Integrated PBPK/PD
700 Coupled mechanistic pathway model (miRNA-BDNF): an approach towards
701 System toxicology. *Toxicol. Lett.* 280, 79–91. doi:10.1016/j.toxlet.2017.08.003
- 702 Sharma, R.P., Schuhmacher, M., Kumar, V., 2016. Review on crosstalk and common
703 mechanisms of endocrine disruptors: Scaffolding to improve PBPK/PD model of
704 EDC mixture. *Environ. Int.* 14. doi:10.1016/j.envint.2016.09.016
- 705 US Environmental Protection Agency, 2011. Exposure Factors Handbook: 2011
706 Edition. U.S. Environ. Prot. Agency EPA/600/R-, 1–1466. doi:EPA/600/R-
707 090/052F
- 708 Völkel, W., Colnot, T., Csanády, G.A., Filser, J.G., Dekant, W., 2002. Metabolism and
709 kinetics of bisphenol a in humans at low doses following oral administration.
710 *Chem. Res. Toxicol.* 15, 1281–1287. doi:10.1021/tx025548t
- 711 Volle, D.H., Maggi, A., Casati, L., Sendra, R., Sibilía, V., Celotti, F., 2015. Endocrine
712 disruptors: the new players able to affect the epigenome Epigenetics: What are
713 the Mechanisms? *Front. Cell Dev. Biol.* 3. doi:10.3389/fcell.2015.00037
- 714 von Goetz, N., Pirow, R., Hart, A., Bradley, E., Poças, F., Arcella, D., Lillegard, I.T.L.,
715 Simoneau, C., van Engelen, J., Husoy, T., Theobald, A., Leclercq, C., 2017.
716 Including non-dietary sources into an exposure assessment of the European Food
717 Safety Authority: The challenge of multi-sector chemicals such as Bisphenol A.
718 *Regul. Toxicol. Pharmacol.* 85, 70–78. doi:10.1016/j.yrtph.2017.02.004
- 719 Watkins, D.J., Sánchez, B.N., Téllez-Rojo, M.M., Lee, J.M., Mercado-García, A., Blank-
720 Goldenberg, C., Peterson, K.E., Meeker, J.D., 2017. Phthalate and bisphenol A
721 exposure during in utero windows of susceptibility in relation to reproductive

- 722 hormones and pubertal development in girls. Environ. Res. 159, 143–151.
723 doi:10.1016/j.envres.2017.07.051
- 724 WHO, F. and A.O. of the U.N., 2010. Toxicological and Health Aspects of Bisphenol A.
725 World Heal. Organ. 60.
- 726 Wormuth, M., Scheringer, M., Vollenweider, M., Hungerbühler, K., 2006. What are the
727 sources of exposure to eight frequently used phthalic acid esters in Europeans?
728 Risk Anal. 26, 803–824. doi:10.1111/j.1539-6924.2006.00770.x
- 729 Zhu, Y., Gao, H., Huang, K., Zhang, Y., Cai, X., Yao, H., Mao, L., Ge, X., Zhou, S., Xu,
730 Y., Jin, Z., Sheng, J., Yan, S., Pan, W., Hao, J., Zhu, P., Tao, F., 2018. Prenatal
731 phthalate exposure and placental size and shape at birth: A birth cohort study.
732 Environ. Res. 160, 239–246. doi:10.1016/j.envres.2017.09.012
- 733
- 734
- 735

736 Table 1. Characteristics of the study population from Reus cohort, Tarragona (Spain) (n=72).
737

Characteristics of the study population (n = 72)	%
<i>Maternal age at delivery (years)</i>	
< 20	1
20-29	14
30-39	72
>40	13
<i>Twin pregnancy</i>	
	8
<i>Maternal pre-pregnancy BMI*</i>	
Underweight (<19kg/m ²)	6
Normal (19-25 kg/m ²)	50
Overweight (>25 kg/m ²)	25
Obese (>30 kg/m ²)	19
<i>Maternal pregnancy (20 GW) BMI*</i>	
Underweight (<19kg/m ²)	1
Normal (19-25 kg/m ²)	41
Overweight (>25 kg/m ²)	37
Obese (>30 kg/m ²)	21
<i>Maternal education</i>	
Primary	28
Secondary	31
University	41
<i>Social economic status</i>	
Low level (< 9000-19000€/year)	24
Median level (19000-35000€/year)	49
High level (> 35000 €/year)	27
<i>Maternal country of origin</i>	
Spain	76
Other	24
<i>Marital Status</i>	
Living with the father	99
Not living with the father	1
<i>Maternal smoking</i>	
Never smoke	73
Not during pregnancy	9
During pregnancy	18

*BMI= Body mass index

738

739

740

741

742

743

744 Table 2. Monte-Carlo parameter description to assess the total dermal contribution of BPA and DEHP.

Parameter	Symbol	units	Type	Distribution	Reference
DEHP concentration in	C_{DEHP}	-	-	-	-
Lipstick	-	$\mu\text{g/g}$	T	1.79 (0-6.45)	Guo and Kannan, 2013
Body lotion	-	$\mu\text{g/g}$	T	0.96 (0-11.3)	Guo and Kannan, 2013
Face cream	-	$\mu\text{g/g}$	T	0.4 (0-2.45)	Guo and Kannan, 2013
Shampoo	-	$\mu\text{g/g}$	T	0.1 (0-1.1)	Esteve et al., 2016
Shower gel	-	$\mu\text{g/g}$	U	9.53-32.4	Guo et al., 2013
Deodorant	-	$\mu\text{g/g}$	T	4.98 (0-65.3)	Guo and Kannan, 2013
Hair conditioner	-	$\mu\text{g/g}$	T	0.18 (0-0.39)	Guo and Kannan, 2013
Spray perfume	-	$\mu\text{g/g}$	T	15 (7-130)	Wormuth et al., 2006
Eye shadow	-	$\mu\text{g/g}$	T	0.64 (0-1.46)	Guo and Kannan, 2013
BPA concentration in	C_{BPA}	-	-	-	-
Body lotion	-	$\mu\text{g/g}$	LN ^a	$3.54 \cdot 10^{-04}$, $1.18 \cdot 10^{-02}$, $1.67 \cdot 10^{-01}$	Liao and Kannan, 2014
Face cream	-	$\mu\text{g/g}$	LN	0.03 ± 0	Cacho et al., 2013
Liquid foundation	-	$\mu\text{g/g}$	LN ^a	0,0.02,0.04	Liao and Kannan, 2014
Shampoo	-	$\mu\text{g/g}$	LN	0.09 ± 0	Cacho et al., 2013
Shower gel	-	$\mu\text{g/g}$	LN	0.07 ± 0	Cacho et al., 2013
PCP frequency	PCP_{fr}	-	-	-	-
Lipstick	-	Application/day	N	0.18 ± 0.34	Present study
Body lotion	-	Application/day	N	0.78 ± 0.41	Present study
Face cream	-	Application/day	N	0.72 ± 0.44	Present study
Liquid foundation	-	Application/day	N	0.42 ± 0.44	Present study
Shampoo	-	Application/day	N	0.62 ± 0.37	Present study
Shower gel	-	Application/day	N	0.92 ± 0.31	Present study
Deodorant	-	Application/day	N	0.94 ± 0.27	Present study
Hair conditioner	-	Application/day	N	0.35 ± 0.28	Present study
Spray perfume	-	Application/day	N	0.68 ± 0.45	Present study
Eye shadow	-	Application/day	N	0.42 ± 0.44	Present study
PCP amount	PCP_a	-	-	-	-
Lipstick	-	g/application	LN ^g	0.01 ± 3.29	Loretz et al., 2005
Body lotion	-	g/application	LN ^g	3.26 ± 2.25	Loretz et al., 2005
Face cream	-	g/application	LN ^g	0.80 ± 2.55	Loretz et al., 2005

Liquid foundation	-	g/application	LN ^g	0.33 ± 2.99	Loretz et al., 2006
Shampoo	-	g/application	G	0.38,5.79,2.15	Loretz et al., 2006
Shower gel	-	g/application	G	0.67,4.89,2.84	Loretz et al., 2006
Deodorant	-	g/application	LN ^g	0.56 ± 2.41	Loretz et al., 2006
Hair conditioner	-	g/application	LN ^g	10.28 ± 2.20	Loretz et al., 2006
Spray perfume	-	g/application	LN ^g	0.30 ± 3.36	Loretz et al., 2006
Eye shadow	-	g/application	LN ^g	0.01 ± 3.61	L. J. Loretz et al., 2008
Body weight	BW _{20GW}	kg	LN	71.42 ± 17.15	Present study
Retention factor (rinse off PCP)	R _f	-	-	-	-
Shampoo	-	-	U	0-0.02	EFSA, 2015
Shower gel	-	-	U	0-0.02	EFSA, 2015
Hair conditioner	-	-	U	0-0.02	EFSA, 2015
Ingestion factor lipstick	1-(Ing _i)	-	LN	0.20 ± 0.04	Franzen et al., 2016
DEHP dermal absorption factor	ABS _(DEHP)	-	U	0.05-0.15	EPA, 2011
BPA dermal absorption factor	ABS _(BPA)	-	U	0.08-0.10	Demierre et al., 2012

LN = Log-normal; T = Triangular; U = Uniform; G = Gamma; N= Normal distribution. Mean, minimum, and maximum values were used for triangular distributions; Mean and standard deviation were used for log-normal distributions; Geometrical mean and geometrical standard deviation were used in log-normal^g distributions; minimum and maximum values were used for uniform distributions; Percentile 50,95 and maximum were used in log-normal^g distributions and location, scale and shape were used for gamma distribution.

746 Table 3. Monte-Carlo parameter description to assess the total non-dietary ingestion contribution of BPA and DEHP.

747

Parameter	Symbol	units	Type	Distribution	Reference
DEHP concentration in	C_{DEHP}	-	-	-	-
Lipstick	-	µg/g	T	1.79 (0-6.45)	Guo and Kannan,2013
Dust indoor	-	µg/kg dust	LN ^b	$1.20 \cdot 10^6$	Wormuth et al., 2006
BPA concentration in	C_{BPA}	-	-	-	-
Toothpaste	-	µg/g	LN ^c	0.35,0.83	Liao and Kannan,2014
Dust indoor	-	µg/kg dust	LN	$2 \cdot 10^3 \pm 2.1 \cdot 10^3$	Geens et al., 2009
PCP frequency	PCP_{fr}	-	-	-	-
Lipstick	-	Application/day	N	0.18 ± 0.34	Present study
Toothpaste	-	Application/day	N	1.82 ± 0.76	Present study
PCP amount	PCP_a	-	-	-	-
Lipstick	-	g/application	LN ^g	0.01 ± 3.29	Loretz et al., 2005
Toothpaste	-	g/application	U	0.79-1.20	McNamara et al., 2007
Dust ingestion rate	I_r	kg/day	N	$3 \cdot 10^{-5} \pm 3 \cdot 10^{-6}$	EPA, 2011
Ingestion factor	Ing_f	-	-	-	-
Lipstick	-	-	LN	0.20 ± 0.04	Franzen et al., 2016
Toothpaste	-	-	U	0-0.10	Angerer et al., 2010
Body weight	BW_{20GW}	kg	LN	71.42 ± 17.15	Present study

LN = Log-normal; T = Triangular; U = Uniform. Mean, minimum, and maximum values were used for triangular distributions; Mean and standard deviation were used for log-normal distributions; Geometrical mean and geometrical standard deviation were used in log-normal^g distributions; minimum and maximum values were used for uniform distributions; Mean and P95 were used for log-normal^b distributions; Percentile 50 and 95 were used in log-normal^c distributions.

748

749

750


751

752 Table 4. Monte-Carlo parameter description to assess the total inhalation contribution of BPA and DEHP.
753

Parameter	Symbol	units	Type	Distribution	Reference
DEHP concentration in	C_{DEHP}	-	-	-	-
Air indoor	-	$\mu\text{g}/\text{m}^3$	T	0.3 (0.05-0.62)	Wormuth et al., 2006
Air outdoor	-	$\mu\text{g}/\text{m}^3$	T	0.01 (0-0.05)	Wormuth et al., 2006
BPA concentration in	C_{BPA}	-	-	-	-
Air indoor	-	$\mu\text{g}/\text{m}^3$	T	0 (0-0.01)	EFSA, 2015
Air outdoor	-	$\mu\text{g}/\text{m}^3$	LN	0.01 ± 0.01	Salapasidou et al., 2011
Inhalation rate					
sleeping	$lh_{r \text{ sleep}}$	m^3/min	LN ^b	0,0.01	EPA, 2011
sedentary activity	$lh_{r \text{ sedentary}}$	m^3/min	LN ^b	0,0.01	EPA, 2011
moderate activity	$lh_{r \text{ moderate}}$	m^3/min	LN ^b	0.02,0.03	EPA, 2011
Time sleeping	t_{sleep}	min	N	521 ± 52.10	IEC, 2012
Time outdoor	t_{outdoor}	min	N	106 ± 10.60	IEC, 2012
Time indoor	t_{indoor}	min	-	1440	-
Body weight	BW_{20GW}	kg	LN	71.42 ± 17.15	Present study

Time indoor= 24 hours – ($T_{\text{sleep}} + T_{\text{outdoor}}$). LN = Log-normal; T = Triangular. Mean, minimum, and maximum values were used for triangular distributions; Mean and standard deviation were used for log-normal distributions; Mean and P95 were used for log-normal^b distributions.

754



755


756

757

758

759

Figure 1. Non-dietary exposure (dermal contact, non-dietary ingestion and inhalation) Reus (Tarragona, Spain) pregnant women cohort exposure to BPA and DEHP exposure. Results are given in mean (5th; 95th percentile).



760

761


762

763


764

765

Figure 2. Total mean exposure dietary (Martínez et al., 2017) and non-dietary (dermal, non-dietary ingestion and inhalation) to BPA and DEHP for Reus pregnant women cohort. Results are given in mean (5th; 95th percentile).




766




767

768 **Figure 3.** Time versus BPA plasma concentration for mothers a), and fetuses b), considering six
 769 different exposure scenarios (the 5th percentile diet; the 5th percentile diet + non-diet; mean diet;
 770 mean diet + non-diet; the 95th percentile diet and the 95th percentile diet + non-diet). It was
 771 considered three-food intake dose for diet and non-diet (dermal and dust ingestion) keeping
 772 inhalation as a continuous exposure.



773



774

775 **Figure 4.** Time versus MEHP plasma concentration for mothers c) and fetuses d), considering
776 six different exposure scenarios (the 5th percentile diet; the 5th percentile diet + non-diet; mean
777 diet; mean diet + non-diet; the 95th percentile diet and the 95th percentile diet + non-diet). It was
778 considered one-food intake dose for diet and non-diet (dermal and dust ingestion) keeping
779 inhalation as a continuous exposure.